AIM: Defined daily dose (DDD) is the most common measurement unit used in drug consumption studies. The DDD for opioids may not reflect their relative clinical potencies. The aim of this study was to explore whether opioid consumption data may be interpreted differently when adding oral morphine equivalent (OMEQ) dose as a measurement unit compared with using DDD. METHODS: The equianalgesic ratio of each opioid relative to morphine was tabulated. Data on opioid consumption expressed in DDD were converted to OMEQs using the equianalgesic ratios. The opioid consumption was compared in three different study settings: clinical data from an opioid switching study, trends within one country and a comparison between countries. RESULTS: Using DDD, the opioid consumption in Norway between 2004-2008 increased of 6.7%, while the increase was 23.6% using OMEQ. While DDD/1000 inhabitants/day showed that Sweden had the highest consumption of opioids among the Nordic countries, OMEQ/1000 inhabitants/day showed that Denmark had the highest consumption. In the switching study DDD indicated a reduction in analgesic dosing and OMEQ an increase when switching from WHO step II to III. CONCLUSION: OMEQ reflects clinical dosing better than DDD, and can give additional insight into opioid consumption when combined with DDD. Using OMEQ can also lead to different conclusions in opioid consumption studies compared with using DDD alone.
AIM: Defined daily dose (DDD) is the most common measurement unit used in drug consumption studies. The DDD for opioids may not reflect their relative clinical potencies. The aim of this study was to explore whether opioid consumption data may be interpreted differently when adding oral morphine equivalent (OMEQ) dose as a measurement unit compared with using DDD. METHODS: The equianalgesic ratio of each opioid relative to morphine was tabulated. Data on opioid consumption expressed in DDD were converted to OMEQs using the equianalgesic ratios. The opioid consumption was compared in three different study settings: clinical data from an opioid switching study, trends within one country and a comparison between countries. RESULTS: Using DDD, the opioid consumption in Norway between 2004-2008 increased of 6.7%, while the increase was 23.6% using OMEQ. While DDD/1000 inhabitants/day showed that Sweden had the highest consumption of opioids among the Nordic countries, OMEQ/1000 inhabitants/day showed that Denmark had the highest consumption. In the switching study DDD indicated a reduction in analgesic dosing and OMEQ an increase when switching from WHO step II to III. CONCLUSION:OMEQ reflects clinical dosing better than DDD, and can give additional insight into opioid consumption when combined with DDD. Using OMEQ can also lead to different conclusions in opioid consumption studies compared with using DDD alone.
Authors: Lars Morten Skollerud; Olav Ms Fredheim; Kristian Svendsen; Svetlana Skurtveit; Petter C Borchgrevink Journal: Support Care Cancer Date: 2012-06-01 Impact factor: 3.603
Authors: Aaron M Gilson; Martha A Maurer; Karen M Ryan; Paul J Rathouz; James F Cleary Journal: J Pain Symptom Manage Date: 2012-09-24 Impact factor: 3.612
Authors: Alex H Kral; Lynn Wenger; Scott P Novak; Daniel Chu; Karen F Corsi; Diana Coffa; Brad Shapiro; Ricky N Bluthenthal Journal: Drug Alcohol Depend Date: 2015-05-22 Impact factor: 4.492
Authors: Arjan G J Bot; Stijn Bekkers; Paul M Arnstein; R Malcolm Smith; David Ring Journal: Clin Orthop Relat Res Date: 2014-04-29 Impact factor: 4.176
Authors: Phillip O Coffin; Emily Behar; Christopher Rowe; Glenn-Milo Santos; Diana Coffa; Matthew Bald; Eric Vittinghoff Journal: Ann Intern Med Date: 2016-06-28 Impact factor: 25.391
Authors: Andrea L Schaffer; Nicholas A Buckley; Louisa Degenhardt; Briony Larance; Rose Cairns; Timothy A Dobbins; Sallie-Anne Pearson Journal: CMAJ Date: 2018-03-26 Impact factor: 8.262
Authors: Christine M Wilder; Shannon C Miller; Elizabeth Tiffany; Theresa Winhusen; Erin L Winstanley; Michael D Stein Journal: J Addict Dis Date: 2016